

**Response document for MHRA public consultation on the
proposal to make Maloff Protect available in Pharmacies
Ref: ARM93**

Your details

Name: [REDACTED]

Position (if applicable): Chief Executive

Organisation (if applicable):Dispensing Doctors' Association

Email: [REDACTED]

1. Do you consider that Maloff Protect should be available as a Pharmacy medicine?

No ☐

Please provide any comments or evidence to support your response:

Our concern is that the person could purchase the OTC, but that it may not be the appropriate medication for the malaria area they are going to.

2. Do you have any specific comments on the leaflet or the label provided in the public reclassification report for Maloff Protect?

Please see above. There needs to be a warning that it might not be the most appropriate medication for the area of the world the person is travelling to and thus they may not be fully protected.

3. Do you have any other comments on the reclassification?

Please see above.

4. The MHRA may publish consultation responses. Do you want your response to remain confidential?

No ☐

*If partially, please indicate which parts you wish to remain confidential. In line with the Freedom of Information Act 2000, if we receive a request for disclosure of the information we will take full account of your explanation, but we cannot give an assurance that confidentiality can be maintained in all circumstances. Responses to consultation will not normally be released under FOI until the regulatory process is complete.

Responses can be continued onto a separate page if required. This form should be returned by email (reclassification@mhra.gsi.gov.uk) to arrive by **6 April 2017**. Contributions received after that date cannot be included in the exercise.